Obstet Gynecol:预防性服用普瑞巴林可减轻药物流产期间的疼痛

2018-08-11 xing.T MedSci原创

由此可见,与安慰剂相比,药物流产期间300mg普瑞巴林与米索前列醇联合使用并未显著降低最大疼痛评分。接受普瑞巴林治疗的妇女不太可能需要布洛芬或麻醉剂治疗,尽管眩晕、嗜睡和视力模糊发生几率增加,但镇痛的满意度更高。

近日,妇产科权威杂志Obstetrics and Gynecology上发表了一研究文章,研究人员旨在评估预防性普瑞巴林是否可以减少药物流产时的疼痛。

研究人员对妊娠70天内采用米非司酮和口含米索前列醇开始药物流产的妇女进行了一项随机、双盲、安慰剂对照试验。在服用米索前列醇之前,参与者被随机分配至300mg口服普瑞巴林或安慰剂治疗。该研究的主要结局是11分数字评定量表的最大疼痛,使用72小时的实时电子调查报告。次要结局包括每个时间点的疼痛、布洛芬和麻醉剂的使用、副作用和满意度。研究人员估计了110名女性需要有80%的效能才能发现1.3分的疼痛差异。

在2015年6月至2016年10月期间,研究人员筛查了241名女性,随机分配了110名女性(56名普瑞巴林组,54名安慰剂组)。3人失访,普瑞巴林组与安慰剂组平均最大疼痛的主要结局分别为5.0±2.6 vs. 5.5±2.2(P=0.32)。不包括在研究胶囊之前服用的药物,普瑞巴林组64%(35/55)和安慰剂组87%(45/52)的参与者服用了布洛芬(P<0.01)。普瑞巴林组29%(16/55)和安慰剂组50%(26/52)的参与者使用了麻醉药(P<0.03)。普瑞巴林组更多参与者出现眩晕(P<0.001)、嗜睡(P<0.04)和视力模糊(P<0.05)。普瑞巴林组镇痛方案的满意度评分较高(非常满意:47% vs. 22%; P=0.006)。

由此可见,与安慰剂相比,药物流产期间300mg普瑞巴林与米索前列醇联合使用并未显著降低最大疼痛评分。接受普瑞巴林治疗的妇女不太可能需要布洛芬或麻醉剂治疗,尽管眩晕、嗜睡和视力模糊发生几率增加,但镇痛的满意度更高。

原始出处:

A Friedlander, EmmaKate B, et al. Prophylactic Pregabalin to Decrease Pain During Medication Abortion: A Randomized Controlled Trial.Obstetrics & Gynecology.2018. https://journals.lww.com/greenjournal/Abstract/publishahead/Prophylactic_Pregabalin_to_Decrease_Pain_During.97970.aspx

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2011386, encodeId=842520113869e, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Apr 18 12:02:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034791, encodeId=37412034e9164, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Nov 22 20:02:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044063, encodeId=d66a20440637c, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Oct 28 13:02:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310301, encodeId=e9a9131030103, content=<a href='/topic/show?id=24795994515' target=_blank style='color:#2F92EE;'>#普瑞巴林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59945, encryptionId=24795994515, topicName=普瑞巴林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Mon Aug 13 10:02:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592068, encodeId=d47515920689d, content=<a href='/topic/show?id=b6b48e79591' target=_blank style='color:#2F92EE;'>#药物流产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87795, encryptionId=b6b48e79591, topicName=药物流产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da7118077945, createdName=dangious, createdTime=Mon Aug 13 10:02:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337964, encodeId=aa4833e96415, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Sat Aug 11 19:31:16 CST 2018, time=2018-08-11, status=1, ipAttribution=)]
    2019-04-18 yhy100200
  2. [GetPortalCommentsPageByObjectIdResponse(id=2011386, encodeId=842520113869e, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Apr 18 12:02:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034791, encodeId=37412034e9164, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Nov 22 20:02:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044063, encodeId=d66a20440637c, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Oct 28 13:02:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310301, encodeId=e9a9131030103, content=<a href='/topic/show?id=24795994515' target=_blank style='color:#2F92EE;'>#普瑞巴林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59945, encryptionId=24795994515, topicName=普瑞巴林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Mon Aug 13 10:02:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592068, encodeId=d47515920689d, content=<a href='/topic/show?id=b6b48e79591' target=_blank style='color:#2F92EE;'>#药物流产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87795, encryptionId=b6b48e79591, topicName=药物流产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da7118077945, createdName=dangious, createdTime=Mon Aug 13 10:02:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337964, encodeId=aa4833e96415, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Sat Aug 11 19:31:16 CST 2018, time=2018-08-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2011386, encodeId=842520113869e, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Apr 18 12:02:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034791, encodeId=37412034e9164, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Nov 22 20:02:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044063, encodeId=d66a20440637c, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Oct 28 13:02:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310301, encodeId=e9a9131030103, content=<a href='/topic/show?id=24795994515' target=_blank style='color:#2F92EE;'>#普瑞巴林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59945, encryptionId=24795994515, topicName=普瑞巴林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Mon Aug 13 10:02:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592068, encodeId=d47515920689d, content=<a href='/topic/show?id=b6b48e79591' target=_blank style='color:#2F92EE;'>#药物流产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87795, encryptionId=b6b48e79591, topicName=药物流产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da7118077945, createdName=dangious, createdTime=Mon Aug 13 10:02:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337964, encodeId=aa4833e96415, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Sat Aug 11 19:31:16 CST 2018, time=2018-08-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2011386, encodeId=842520113869e, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Apr 18 12:02:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034791, encodeId=37412034e9164, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Nov 22 20:02:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044063, encodeId=d66a20440637c, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Oct 28 13:02:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310301, encodeId=e9a9131030103, content=<a href='/topic/show?id=24795994515' target=_blank style='color:#2F92EE;'>#普瑞巴林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59945, encryptionId=24795994515, topicName=普瑞巴林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Mon Aug 13 10:02:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592068, encodeId=d47515920689d, content=<a href='/topic/show?id=b6b48e79591' target=_blank style='color:#2F92EE;'>#药物流产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87795, encryptionId=b6b48e79591, topicName=药物流产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da7118077945, createdName=dangious, createdTime=Mon Aug 13 10:02:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337964, encodeId=aa4833e96415, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Sat Aug 11 19:31:16 CST 2018, time=2018-08-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2011386, encodeId=842520113869e, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Apr 18 12:02:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034791, encodeId=37412034e9164, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Nov 22 20:02:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044063, encodeId=d66a20440637c, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Oct 28 13:02:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310301, encodeId=e9a9131030103, content=<a href='/topic/show?id=24795994515' target=_blank style='color:#2F92EE;'>#普瑞巴林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59945, encryptionId=24795994515, topicName=普瑞巴林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Mon Aug 13 10:02:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592068, encodeId=d47515920689d, content=<a href='/topic/show?id=b6b48e79591' target=_blank style='color:#2F92EE;'>#药物流产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87795, encryptionId=b6b48e79591, topicName=药物流产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da7118077945, createdName=dangious, createdTime=Mon Aug 13 10:02:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337964, encodeId=aa4833e96415, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Sat Aug 11 19:31:16 CST 2018, time=2018-08-11, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2011386, encodeId=842520113869e, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Apr 18 12:02:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034791, encodeId=37412034e9164, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Nov 22 20:02:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044063, encodeId=d66a20440637c, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Oct 28 13:02:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310301, encodeId=e9a9131030103, content=<a href='/topic/show?id=24795994515' target=_blank style='color:#2F92EE;'>#普瑞巴林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59945, encryptionId=24795994515, topicName=普瑞巴林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Mon Aug 13 10:02:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592068, encodeId=d47515920689d, content=<a href='/topic/show?id=b6b48e79591' target=_blank style='color:#2F92EE;'>#药物流产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87795, encryptionId=b6b48e79591, topicName=药物流产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da7118077945, createdName=dangious, createdTime=Mon Aug 13 10:02:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337964, encodeId=aa4833e96415, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Sat Aug 11 19:31:16 CST 2018, time=2018-08-11, status=1, ipAttribution=)]
    2018-08-11 orangesking

    0

相关资讯

NEJM:普瑞巴林不能改善急性和慢性坐骨神经痛

普瑞巴林在神经病理性疼痛的有效治疗某些类型,但最新的临床结果表明,普瑞巴林对于坐骨神经痛未表现出显著治疗效果

ACG 2016:Lyrica可改善肠易激综合的症状征

ACG 2016上呈现的随机对照试验试点结果数据显示,Lyrica可改善肠易激综合征患者的症状,包括总体症状、腹痛、腹胀和腹泻。 Lyrica (pregabalin, Pfizer)是γ-氨基丁酸的结构衍生物,和一种钙通道α2δ亚基配体,具有镇痛和抗焦虑活性。FDA批准用于神经病理性疼痛和纤维肌痛等,此外还有非FDA批准的用途,如广泛性焦虑症和不安腿综合征。 来自罗切斯特梅奥诊所的Y

治疗神经性疼痛:普瑞巴林是良药

根据在线发表于9月9日的《疼痛实践》上的研究结果,不管之前有没有用过加巴喷丁,普瑞巴林对于神经性疼痛的治疗都是有益的。 来自纽约罗彻斯特大学医学院的John D. Markman博士和同事们收集了来自在神经性疼痛患者身上进行的18项有关普瑞巴林的随机、双盲试验。作者们比较了普瑞巴林介导的疼痛改变和疼痛相关的睡眠干预得分、最终患者整体印象变化分数以及不良反应在那些之前接受和未接受加巴喷丁的

Neurology:孕早期普瑞巴林服用过多增加胎儿生长缺陷风险

普瑞巴林是用于治疗疼痛(尤其是神经痛和肌肉痛)、癫痫、焦虑和其他精神疾病的常用药物。研究人员尚不清楚该药物的具体作用原理,通常认为它可与大脑的神经细胞受体结合,以减少疼痛神经通路的传导。 洛桑大学医院的Ursula Winterfeld博士指出,通过进行动物研究,他们发现孕妇使用普瑞巴林会增加胎儿出生缺陷的风险。由于孕妇的使用剂量和数据信息并不全面,因为,他们表示所获得的信息十分有限。Winter

Neurology:妊娠早期使用普瑞巴林会增加先天性畸形的风险吗?

研究结果并没有证实普瑞巴林具有致畸作用,尽管不能排除其影响的可能性。

Pain:围手术期该不该使用普瑞巴林?争议仍将继续

目前关于围手术期使用普瑞巴林以预防慢性疼痛的疗效仍存在争议,为此本研究进行了此系统回顾和荟萃分析。 研究人员检索了MEDLINE、EMBASE、LILACS、Cochrane以及临床试验登记数据库及其他数据库相关文章,纳入对比了普瑞巴林治疗组和安慰剂组的随机对照试验研究。主要研究结果为术后3个月慢性疼痛的发生率(CPSP)。次要研究终点为术后第3、6和12个月时的CPSP,以及该相应时间点慢